mySHARED
Shared MHC-bound target discovery — ImmunoEngine for cohorts
Our ImmunoEngine pipeline is also optimized for large cohort analyses allowing shared target discovery in specific cancer patient populations. We perform custom discovery for vaccine and T-cell therapeutics developers, identifying and prioritizing MHC-bound targets using our advanced prediction models. Through our expertise in whole genome target discovery, we find more, better, and novel (dark) targets, including camyotopes, increasing the likelihood for broad population coverage.
What mySHARED delivers
We offer large-scale patient cohort analyses with an average turnaround time of 2–3 months:
- Genome-wide association studies → linking genetic variation to phenotypes such as treatment response, disease progression, or therapeutic targets
- Differential expression and translation analysis
- Presentation prediction: identification of MHC-presented epitopes on both MHC-I and MHC-II molecules
- Immunogenicity prediction: identification of presented epitopes recognized by both CD4 and CD8 immune cells
- Coverage optimization: matching antigen targets with population of interest for optimal coverage
- Final epitope selection: based on antigen score, clonality, functional relevance, and immune-escape likelihood
- myCONSTRUCT: next-generation string-of-beads design (optional)
- myRNA: next-generation codon optimization (optional)
Frequently asked questions about mySHARED
What is mySHARED?
mySHARED uses ImmunoEngine for large cohort analyses to discover shared MHC-bound targets in specific cancer populations, including novel dark targets and camyotopes.
Who is mySHARED for?
mySHARED supports vaccine and T-cell therapeutics developers seeking shared antigens with strong population coverage.
What is the typical turnaround for mySHARED?
Large-scale patient cohort analyses with mySHARED have an average turnaround time of 2–3 months.
Ready to use mySHARED?
Talk to our team about integrating mySHARED into your discovery or development workflow.